• Globe Newswire

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

Globenewswire -

• Globe Newswire

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Globenewswire -

• Globe Newswire

Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology

Globenewswire -

• Globe Newswire

Workplace Options Unveils Comprehensive & Compassionate Return-to-Work Program for Cancer Survivors

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Globenewswire -

• Globe Newswire

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition